Multiple Sulfatase Deficiency: Catalytically Inactive Sulfatases Are Expressed from Retrovirally Introduced Sulfatase Cdnas

Total Page:16

File Type:pdf, Size:1020Kb

Multiple Sulfatase Deficiency: Catalytically Inactive Sulfatases Are Expressed from Retrovirally Introduced Sulfatase Cdnas Proc. Natl. Acad. Sci. USA Vol. 89, pp. 2561-2565, April 1992 Medical Sciences Multiple sulfatase deficiency: Catalytically inactive sulfatases are expressed from retrovirally introduced sulfatase cDNAs WINFRIED ROMMERSKIRCH AND KURT VON FIGURA Georg-August-Universitlit, Abteilung Biochemie II, Gosslerstrasse 12d, D-3400 Gdttingen, Federal Republic of Germany Communicated by Elizabeth F. Neufeld, December 18, 1991 (receivedfor review November 18, 1991) ABSTRACT Multiple sulfatase deficiency (MSD) is an We studied the expression of two lysosomal sulfatases, inherited lysosomal storage disease characterized by the defi- arylsulfatase A (ASA) and arylsulfatase B (ASB), and the ciency of at least seven sulfatases. The basic defect in MSD is microsomal steroid sulfatase (STS). In accordance with the thought to be in a post-translational modification common to all current hypothesis we observed normal amounts of RNA for sulfatases. In accordance with this concept, RNAs of normal ASA, ASB, and STS in group I MSD fibroblasts. More size and amount were detected in MSD fibroblasts for three important, expression ofthe cDNAs for ASA, ASB, and STS sulfatases tested. cDNAs encoding arylsulfatase A, arylsulfa- led to the synthesis of inactive polypeptides in MSD fibro- tase B, or steroid sulfatase were introduced into MSD fibro- blasts and to catalytically active sulfatase polypeptides in blasts and fibroblasts with a single sulfatase deficiency by fibroblasts from patients with a single sulfatase deficiency. retroviral gene transfer. Infected fibroblasts overexpressed the Our results clearly demonstrate that the basic defect in MSD respective sulfatase polypeptides. While in single-sulfatase- affects a co- or post-translational modification that makes deficiency fibroblasts a concomitant increase of sulfatase ac- sulfatase polypeptides active or prevents their inactivation. tivities was observed, MSD fibroblasts expred sulfatase polypeptides with a severely diminished catalytic activity. From these results we conclude that the mutation in MSD MATERIALS AND METHODS severely decreases the capacity of a co- or post-translational Cell Lines and Cell Culture. The MSD fibroblasts were process that renders sulfatases enzymatically active or prevents obtained from J. Couchot (Clinic de Pediatrie et Puericulture, their premature inactivation. Reims) and E. Christenson (Rigshospitalet, Copenhagen). The MLD fibroblasts deficient in ASA activity, the Maro- Multiple sulfatase deficiency (MSD) is a rare autosomal teaux-Lamy fibroblasts deficient in ASB, and the chromo- recessively transmitted lysosomal storage disorder charac- some X-linked ichthyosis fibroblasts deficient in STS were terized by the accumulation of sulfated lipids and carbohy- obtained from R. Gitzelmann (Kinderhospital, Zurich), J. drates. The disorder is caused by partial deficiencies of at Zimmer (Humangenetik, Freiburg), and the Human Genetic least six lysosomal and one microsomal sulfatase (1). MSD is Cell Repository (Lyon). The packaging cell line PA 317 (12) clinically and biochemically heterogenous. On the basis of was kindly provided by K. Pfitzenmeyer (Klinische For- the residual activities of sulfatases, MSD patients can be schergruppe der Max-Planck-Gesellshaft, Gottingen) and the classified in two groups. Patients of group I exhibit severe retroviral vector pXT1 (13) by E. Wagner (Research Institute sulfatase deficiencies and a neonatal onset ofthe disease, and of Molecular Pathology, Vienna). patients ofgroup II show moderate sulfatase deficiencies (2). Human fibroblasts were maintained at 370C, under 5% CO2 The primary defect in MSD is unknown. The mutations in in minimal essential medium containing 15-20% fetal calf MSD and single sulfatase deficiencies [e.g., metachromatic serum. The culture medium was changed every 3-4 days. leukodystrophy (MLD), mucopolysaccharidosis II, IIIA, and The packaging cell line PA 317 was cultured in Dulbecco's IV, and chromosome X-linked ichthyosis] are nonallelic as modified Eagle's medium with 10% fetal calf serum. shown by complementation studies (3-6). The primary defect RNA Isolation, Northern Blot Hybridization, and Probes. in MSD affects the stability and the catalytic properties of Total RNA of 1-3 x 107 cultured human fibroblasts was sulfatases to a variable extent depending on the type of prepared as described (14). Total RNA in 20 gl of 20 mM sulfatase and the MSD cell line (2, 7-9). This led to the morpholinopropanesulfonic acid (Mops), pH 6.8/6% form- hypothesis that the mutations in MSD affect a gene product aldehyde/33% formamide was heated for 10 min to 70'C and that interacts with sulfatases co- or post-translationally. This electrophoresed through a 1.3% denaturing agarose gel con- process-shared by all sulfatases-is thought to activate taining 0.7% formaldehyde in 20 mM Mops, pH 6.8, and and/or stabilize the sulfatases (2, 8). transferred to Hybond-N membranes (Amersham). To test this hypothesis we analyzed the expression of The radioactive probes for Northern blot analysis were sulfatases in MSD fibroblasts on the RNA level and intro- prepared by the multiprime DNA labeling system (Amer- duced the cDNAs of sulfatases into MSD fibroblasts via sham) with the ASA cDNA insert of pBEH/HT14-CP 18 (15) retroviral gene transfer. According to the working hypothe- and the STS cDNA insert pBEH-STS (16). Filters were sis, sulfatase genes and their transcription should be normal hybridized 16 hr at 420C in 10 mM Tris HCl, pH 7.4, con- in MSD, while expression ofthe endogenous genes and ofthe taining 48% (vol/vol) formamide, 10% dextran sulfate (Phar- introduced cDNAs should yield sulfatase polypeptides that macia LKB) 4.8x SSC, lx Denhardt's solution, salmon are inactive and/or unstable. On the other hand, expression sperm DNA at 100 pg/ml, 1% SDS, and 1-2 x 106 cpm of of the same cDNAs in cells with single sulfatase deficiencies [32P]DNA per ml (lx SSC = 0.15 M NaCl/0.015 M sodium caused by mutations in the sulfatase genes should yield sulfatase polypeptides with normal catalytic properties and Abbreviations: ASA, arylsulfatase A (cerebroside-3-sulfate 3-sulfo- stability, as was shown recently (10, 11). hydrolase, EC 3.1.6.8); pdASA, pseudodeficiency allele of ASA; ASB, arylsulfatase B (N-acetylgalactosamine4-sulfate sulfohydro- lase, EC 3.1.6.12); STS, steroid sulfatase (steryl-sulfate sulfohydro- The publication costs of this article were defrayed in part by page charge lase, EC 3.1.6.2); MLD, metachromatic leukodystrophy; MSD, payment. This article must therefore be hereby marked "advertisement" multiple sulfatase deficiency; cfu, colony-forming units; U, enzyme in accordance with 18 U.S.C. §1734 solely to indicate this fact. unit(s). 2561 Downloaded by guest on October 1, 2021 2562 Medical Sciences: Rommerskirch and von Figura Proc. NatL Acad Sci. USA 89 (1992) citrate, pH 7.0; lx Denhardt's solution = 0.02% bovine ASA RTS serum albumin/0.02% Ficoll/0.02% polyvinylpyrrolidone). Filters were washed at 650C once with 2x SSC for 5 min and '1M MS three times for 20 min each with 0.1x SSC. Production of Recombinant Retroviruses. The construction of the retroviral vectors containing the cDNAs of ASA and ASB were described previously (10, 11). For the construct containing the coding part ofthe ASA pseudodeficiency allele (pdASA) a 1828-base-pair (bp) Xho I-Sal I DNA fragment was isolated from the eukaryotic expression vector pBEH- pdASA (17). It contains the entire cDNA for pdASA, 62 bp of 5' untranslated sequence of the ASA cDNA, and 65 bp of simian virus 40 5' untranslated sequence derived from the expression vector. This fragment was ligated into the Xho I site of the retroviral vector pXT1 (13). For construction of the plasmid pXT1STS a Xho I-Sal I DNA fragment from the eukaryotic expression vector pBEH- STS (16) was used. It contains the entire cDNA coding for of simian virus 40 5' untranslated sequence FIG. 1. Northern blot analysis oftotal RNA. (Left) RNA (10 ,g) STS and 65 bp isolated from the group I MSD fibroblasts (Co.) and control fibro- that is part of the expression vector. This fragment was blasts (Br.) was hybridized with an ASA cDNA probe. (Right) RNA ligated into the Xho I site of the retroviral vector pXT1. (5 Zg) isolated from group I MSD fibroblasts (Co.), chromosome For the production of replication-defective infectious ret- X-linked-ichthyosis fibroblasts (800), and control fibroblasts (Br.) roviruses the vectors pXT1ASA, pXT1ASB, and pXT1STS was hybridized with an STS cDNA. The size of the RNA species is were transfected into the helper-virus-free amphotropic indicated in kilobases (kb). Ethidium bromide staining and rehybrid- packaging cell line PA 317 (12) by the calcium phosphate ization with an actin probe revealed that comparable amounts of precipitation technique. Cells were selected with neomycin at RNA had been loaded (not shown). 0.4 mg/ml. Resistant cells were recultured to about 50%o confluency. Selection was withdrawn for 2 days, and the detects RNA species of 6.3, 4.6, and 2.5 kb. The latter tissue culture medium containing the retrovirus was har- represents a minor species detectable only after prolonged vested, centrifuged, filtered through a 0.45-,um-pore filter to exposure. In total RNA from fibroblasts carrying a deletion exclude remaining packaging cells, tested for colony-forming ofthe STS gene (X-linked ichthyosis), none ofthe STS RNA units (cfu) on NIH 3T3 tk- cells, and stored at -80°C until species is detectable. In total RNA from group I MSD used for infection of fibroblasts. Throughout this article the fibroblasts, ASA and STS transcripts of the same size as in retroviral vectors are designated by a p (e.g., pXT1). The p control RNA were detectable. Furthermore, the amounts of will be omitted to designate the corresponding viruses (e.g., ASA and STS transcripts in MSD and control fibroblasts XT1). were comparable (shown for cell line Co. in Fig. 1). Recently Retroviral Gene Transfer. Human fibroblasts were seeded we have reported similar findings for ASB (22).
Recommended publications
  • 1 ICR-Geneset Gene List
    ICR-geneset Gene List. IMAGE ID UniGene Locus Name Cluster 20115 Hs.62185 SLC9A6 solute carrier family 9 (sodium/hydrogen exchanger), isoform 6 21738 21899 Hs.78353 SRPK2 SFRS protein kinase 2 21908 Hs.79133 CDH8 cadherin 8, type 2 22040 Hs.151738 MMP9 matrix metalloproteinase 9 (gelatinase B, 92kD gelatinase, 92kD type IV collagenase) 22411 Hs.183 FY Duffy blood group 22731 Hs.1787 PHRET1 PH domain containing protein in retina 1 22859 Hs.356487 ESTs 22883 Hs.150926 FPGT fucose-1-phosphate guanylyltransferase 22918 Hs.346868 EBNA1BP2 EBNA1 binding protein 2 23012 Hs.158205 BLZF1 basic leucine zipper nuclear factor 1 (JEM-1) 23073 Hs.284244 FGF2 fibroblast growth factor 2 (basic) 23173 Hs.151051 MAPK10 mitogen-activated protein kinase 10 23185 Hs.289114 TNC tenascin C (hexabrachion) 23282 Hs.8024 IK IK cytokine, down-regulator of HLA II 23353 23431 Hs.50421 RB1CC1 RB1-inducible coiled-coil 1 23514 23548 Hs.71848 Human clone 23548 mRNA sequence 23629 Hs.135587 Human clone 23629 mRNA sequence 23658 Hs.265855 SETMAR SET domain and mariner transposase fusion gene 23676 Hs.100841 Homo sapiens clone 23676 mRNA sequence 23772 Hs.78788 LZTR1 leucine-zipper-like transcriptional regulator, 1 23776 Hs.75438 QDPR quinoid dihydropteridine reductase 23804 Hs.343586 ZFP36 zinc finger protein 36, C3H type, homolog (mouse) 23831 Hs.155247 ALDOC aldolase C, fructose-bisphosphate 23878 Hs.99902 OPCML opioid binding protein/cell adhesion molecule-like 23903 Hs.12526 Homo sapiens clone 23903 mRNA sequence 23932 Hs.368063 Human clone 23932 mRNA sequence 24004
    [Show full text]
  • Steroid Sulfatase of Human Leukocytes and Epidermis and the Diagnosis of Recessive X-Linked Ichthyosis
    Steroid sulfatase of human leukocytes and epidermis and the diagnosis of recessive X-linked ichthyosis. E H Epstein Jr, M E Leventhal J Clin Invest. 1981;67(5):1257-1262. https://doi.org/10.1172/JCI110153. Research Article Patients with recessive X-linked ichthyosis, one of the inherited types of excessive stratum corneum cohesion, have deficient steroid sulfatase in fibroblasts grown from their dermis. Because of the expense and long period required to grow such cells, we have assayed this enzyme in peripheral blood leukocytes and found it to be undetectable in those from patients with this type of ichthyosis, but normal in those from patients with other hereditary or acquired types of ichthyosis. In addition, steroid sulfatase activity is less in leukocytes from women who are carriers of this disease than normal women, and this assay can be used to detect such carriers. Despite previous studies demonstrating that the gene for this enzyme escapes the inactivation of other x-chromosome genes, normal women have leukocyte steroid sulfatase activity only 1.3 times that of normal men, suggesting that some gene dosage compensation occurs. Normal human epidermis, the tissue most affected clinically, also expresses steroid sulfatase activity. The epidermal enzyme is similar in its subcellular localization, its molecular size, and kinetically to that of placenta, leukocytes, and fibroblasts. Find the latest version: https://jci.me/110153/pdf Steroid Sulfatase of Human Leukocytes and Epidermis and the Diagnosis of Recessive X-linked Ichthyosis ERVIN H. EPSTEIN, JR., and MARY E. LEVENTHAL, Dermatology Unit of the Medical Service, San Francisco General Hospital Medical Center, Department of Dermatology, University of California, San Francisco, California 94110 A B S T R A C T Patients with recessive X-linked pearance especially on the side of the neck, and the ichthyosis, one of the inherited types of excessive subsequently described comeal stippling (2).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown Et Al
    US 20030082511A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown et al. (43) Pub. Date: May 1, 2003 (54) IDENTIFICATION OF MODULATORY Publication Classification MOLECULES USING INDUCIBLE PROMOTERS (51) Int. Cl." ............................... C12O 1/00; C12O 1/68 (52) U.S. Cl. ..................................................... 435/4; 435/6 (76) Inventors: Steven J. Brown, San Diego, CA (US); Damien J. Dunnington, San Diego, CA (US); Imran Clark, San Diego, CA (57) ABSTRACT (US) Correspondence Address: Methods for identifying an ion channel modulator, a target David B. Waller & Associates membrane receptor modulator molecule, and other modula 5677 Oberlin Drive tory molecules are disclosed, as well as cells and vectors for Suit 214 use in those methods. A polynucleotide encoding target is San Diego, CA 92121 (US) provided in a cell under control of an inducible promoter, and candidate modulatory molecules are contacted with the (21) Appl. No.: 09/965,201 cell after induction of the promoter to ascertain whether a change in a measurable physiological parameter occurs as a (22) Filed: Sep. 25, 2001 result of the candidate modulatory molecule. Patent Application Publication May 1, 2003 Sheet 1 of 8 US 2003/0082511 A1 KCNC1 cDNA F.G. 1 Patent Application Publication May 1, 2003 Sheet 2 of 8 US 2003/0082511 A1 49 - -9 G C EH H EH N t R M h so as se W M M MP N FIG.2 Patent Application Publication May 1, 2003 Sheet 3 of 8 US 2003/0082511 A1 FG. 3 Patent Application Publication May 1, 2003 Sheet 4 of 8 US 2003/0082511 A1 KCNC1 ITREXCHO KC 150 mM KC 2000000 so 100 mM induced Uninduced Steady state O 100 200 300 400 500 600 700 Time (seconds) FIG.
    [Show full text]
  • Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and Is a Therapeutic Target for Advanced Prostate Cancer
    Author Manuscript Published OnlineFirst on September 14, 2020; DOI: 10.1158/1078-0432.CCR-20-1682 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Steroid sulfatase stimulates intracrine androgen synthesis and is a therapeutic target for advanced prostate cancer Cameron M. Armstrong1*, Chengfei Liu1*, Liangren Liu1,2*, Joy C. Yang1, Wei Lou1, Ruining Zhao1,3, Shu Ning1, Alan P. Lombard1, Jinge Zhao1, Leandro S D'Abronzo1, Christopher P. Evans1,4, Pui-Kai Li5, Allen C. Gao1, 4, 6,7 Running title: Targeting steroid sulfatase for advanced prostate cancer Key words: Prostate cancer, steroid sulfatase, resistance, intracrine androgen synthesis, adrenal androgens 1Department of Urologic Surgery, University of California Davis, CA, USA 2Present address: Department of Urology, West China Hospital, Sichuan University, China 3Present address: Department of Urology, General Hospital of Ningxia Medical University, China 4UC Davis Comprehensive Cancer Center, University of California Davis, CA, USA 5Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH, USA 6VA Northern California Health Care System, Sacramento, CA, USA 7Corresponding author: Allen Gao, University of California Davis, 4645 2nd Avenue, Sacramento, CA 95817, USA. Phone: 916-734-8718, email: [email protected] *These authors contributed equally to the work. Conflict of interest: PKL and ACG are co-inventors of a patent application of the selected small molecule inhibitors of steroid sulfatase. 1 Downloaded from clincancerres.aacrjournals.org on October 1, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on September 14, 2020; DOI: 10.1158/1078-0432.CCR-20-1682 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • REVIEW Steroid Sulfatase Inhibitors for Estrogen
    99 REVIEW Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers Atul Purohit and Paul A Foster1 Oncology Drug Discovery Group, Section of Investigative Medicine, Imperial College London, Hammersmith Hospital, London W12 0NN, UK 1School of Clinical and Experimental Medicine, Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Birmingham B15 2TT, UK (Correspondence should be addressed to P A Foster; Email: [email protected]) Abstract Estrogens and androgens are instrumental in the maturation of in vivo and where we currently stand in regards to clinical trials many hormone-dependent cancers. Consequently,the enzymes for these drugs. STS inhibitors are likely to play an important involved in their synthesis are cancer therapy targets. One such future role in the treatment of hormone-dependent cancers. enzyme, steroid sulfatase (STS), hydrolyses estrone sulfate, Novel in vivo models have been developed that allow pre-clinical and dehydroepiandrosterone sulfate to estrone and dehydroe- testing of inhibitors and the identification of lead clinical piandrosterone respectively. These are the precursors to the candidates. Phase I/II clinical trials in postmenopausal women formation of biologically active estradiol and androstenediol. with breast cancer have been completed and other trials in This review focuses on three aspects of STS inhibitors: patients with hormone-dependent prostate and endometrial 1) chemical development, 2) biological activity, and 3) clinical cancer are currently active. Potent STS inhibitors should trials. The aim is to discuss the importance of estrogens and become therapeutically valuable in hormone-dependent androgens in many cancers, the developmental history of STS cancers and other non-oncological conditions.
    [Show full text]
  • Mitochondrial Dysfunction and Organic Aciduria In
    Mitochondrial dysfunction and organic aciduria in five patients carrying mutations in the Ras-MAPK pathway Eva Morava, Tjitske Kleefstra, Saskia Wortmann, Richard Rodenburg, Ernie Mhf Bongers, Kinga Hadzsiev, Lambert van den Heuvel, Willy M Nillessen, Katalin Hollody, Martin Lammens, et al. To cite this version: Eva Morava, Tjitske Kleefstra, Saskia Wortmann, Richard Rodenburg, Ernie Mhf Bongers, et al.. Mitochondrial dysfunction and organic aciduria in five patients carrying mutations in the Ras-MAPK pathway. European Journal of Human Genetics, Nature Publishing Group, 2010, 10.1038/ejhg.2010.171. hal-00591692 HAL Id: hal-00591692 https://hal.archives-ouvertes.fr/hal-00591692 Submitted on 10 May 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Mitochondrial dysfunction and organic aciduria in five patients carrying mutations in the Ras-MAPK pathway Running title: mutations in MAPK and mitochondrial dysfunction Tjitske Kleefstra1+, Saskia B. Wortmann2+, Richard J.T. Rodenburg2,3, Ernie M.H.F. Bongers1, Kinga Hadzsiev4, Cees Noordam5, Lambert
    [Show full text]
  • Chromosomal Microarray, Postnatal, Clarisure® Oligo-SNP
    Diagnostic Services Pediatrics Test Summary Chromosomal Microarray, Postnatal, ClariSure® Oligo-SNP The American College of Medical Genetics (ACMG) Test Code: 16478(X) recommends CMA testing as a first-line genetic test for developmental delay, intellectual disability, ASDs, and Specimen Requirements: 10 mL room-temperature whole multiple congenital anomalies.2,4 This recommendation blood (sodium-heparin, green-top tube); 5 mL minimum is based, in part, on a literature review that included over 21,000 patients with developmental delay/intellectual CPT Code*: 81229 disability, ASDs, or multiple congenital anomalies. The diagnostic yield was 15% to 20% for CMA testing versus ~3% for G-banded karyotyping and ~6% for subtelomeric Clinical Use fluorescence in situ hybridization (FISH) in combination • Determine the genetic etiology of developmental with G-banded karyotyping.5 In individuals with complex delay, intellectual disability, autism spectrum disorders ASDs, CMA testing can result in a diagnostic yield of over (ASDs; pervasive developmental disorders), and 25%.2 ACMG still considers karyotyping a first-line test multiple congenital anomalies when patients are suspected of having a recognizable • Confirm or exclude the diagnosis of known chromosomal syndrome such as trisomy 21 or 18, Turner chromosomal syndromes syndrome, or Klinefelter syndrome.2,4 • Further define ambiguities arising from cytogenetic The oligonucleotide-single nucleotide polymorphism or FISH studies (oligo-SNP) array contains over 2.6 million probes and • Assist in clinical management and genetic counseling covers regions of known and likely CNVs. It can confirm the diagnosis of suspected disorders associated with known Clinical Background chromosomal syndromes and is especially well suited Global developmental delay, intellectual disability (mental for determining the genetic cause of less well-described retardation), ASDs, and multiple congenital anomalies may disorders.
    [Show full text]
  • Design, Synthesis, and Evaluation of Inhibitors of Steroid Sulfatase
    Design, synthesis, and evaluation of inhibitors of steroid sulfatase by Yaser Abdel-Hady Mostafa Abdel-Karem A thesis Presented to the University of Waterloo in fulfilment of the thesis requirement for the degree of Doctor of Philosophy in Chemistry Waterloo, Ontario, Canada, 2014 © Yaser Abdel-Hady Mostafa Abdel-Karem 2014 i Author’s Declaration I hereby declare that I am the sole author of this thesis. This is a true copy of the thesis, including any required final revisions, as accepted by examiners. I understand that my thesis may be made electronically available to public. ii Abstract Steroid sulfatase (STS) catalyzes the desulfation of biologically inactive sulfated steroids to yield biologically active desulfated steroids and is currently being examined as a target for therapeutic intervention for the treatment of breast and other steroid-dependent cancers. A series of 17-arylsulfonamides of 17-aminoestra-1,3,5(10)-trien-3-ol were prepared and evaluated as inhibitors of STS. Introducing n-alkyl groups into the 4´-position of the 17- benzenesulfonamide derivative resulted in an increase in potency with the n-butyl derivative exhibiting the best potency with an IC50 of 26 nM. A further increase in carbon units (to n- pentyl) resulted in a decrease in potency. Branching of the 4´-n-propyl group resulted in a decrease in potency while branching of the 4´-n-butyl group (to a tert-butyl group) resulted in a slight increase in potency (IC50 = 18 nM). Studies with 17-benzenesulfonamides substituted at the 3´- and 4´-positions with small electron donating and electron withdrawing groups revealed the 3´-bromo and 3´-trifluoromethyl derivatives to be excellent inhibitors with IC50‘s of 30 and 23 nM respectively.
    [Show full text]
  • Human Steroid Sulfatase Induces Wnt/Β-Catenin Signaling and Epithelial
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 37), pp: 61604-61617 Research Paper Human steroid sulfatase induces Wnt/β-catenin signaling and epithelial-mesenchymal transition by upregulating Twist1 and HIF-1α in human prostate and cervical cancer cells Sangyun Shin1,*, Hee-Jung Im1,*, Yeo-Jung Kwon1,*, Dong-Jin Ye1, Hyoung-Seok Baek1, Donghak Kim2, Hyung-Kyoon Choi1 and Young-Jin Chun1 1College of Pharmacy and Center for Metareceptome Research, Chung-Ang University, Seoul 06974, Republic of Korea 2Department of Biological Sciences, Konkuk University, Seoul 05029, Republic of Korea *These authors have contributed equally to this work Correspondence to: Young-Jin Chun, email: [email protected] Keywords: steroid sulfatase, epithelial-mesenchymal transition, Wnt/β–catenin pathway, HIF-1α, Twist1 Received: March 06, 2017 Accepted: May 22, 2017 Published: June 27, 2017 Copyright: Shin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Steroid sulfatase (STS) catalyzes the hydrolysis of estrone sulfate and dehydroepiandrosterone sulfate (DHEAS) to their unconjugated biologically active forms. Although STS is considered a therapeutic target for estrogen-dependent diseases, the cellular functions of STS remain unclear. We found that STS induces Wnt/β-catenin s Delete ignaling in PC-3 and HeLa cells. STS increases levels of β-catenin, phospho-β-catenin, and phospho-GSK3β. Enhanced translocation of β-catenin to the nucleus by STS might activate transcription of target genes such as cyclin D1, c-myc, and MMP-7.
    [Show full text]
  • Characterizing Genomic Duplication in Autism Spectrum Disorder by Edward James Higginbotham a Thesis Submitted in Conformity
    Characterizing Genomic Duplication in Autism Spectrum Disorder by Edward James Higginbotham A thesis submitted in conformity with the requirements for the degree of Master of Science Graduate Department of Molecular Genetics University of Toronto © Copyright by Edward James Higginbotham 2020 i Abstract Characterizing Genomic Duplication in Autism Spectrum Disorder Edward James Higginbotham Master of Science Graduate Department of Molecular Genetics University of Toronto 2020 Duplication, the gain of additional copies of genomic material relative to its ancestral diploid state is yet to achieve full appreciation for its role in human traits and disease. Challenges include accurately genotyping, annotating, and characterizing the properties of duplications, and resolving duplication mechanisms. Whole genome sequencing, in principle, should enable accurate detection of duplications in a single experiment. This thesis makes use of the technology to catalogue disease relevant duplications in the genomes of 2,739 individuals with Autism Spectrum Disorder (ASD) who enrolled in the Autism Speaks MSSNG Project. Fine-mapping the breakpoint junctions of 259 ASD-relevant duplications identified 34 (13.1%) variants with complex genomic structures as well as tandem (193/259, 74.5%) and NAHR- mediated (6/259, 2.3%) duplications. As whole genome sequencing-based studies expand in scale and reach, a continued focus on generating high-quality, standardized duplication data will be prerequisite to addressing their associated biological mechanisms. ii Acknowledgements I thank Dr. Stephen Scherer for his leadership par excellence, his generosity, and for giving me a chance. I am grateful for his investment and the opportunities afforded me, from which I have learned and benefited. I would next thank Drs.
    [Show full text]
  • Attention Deficit Hyperactivity Disorder (ADHD) in Phenotypically Similar Neurogenetic Conditions: Turner Syndrome and the Rasopathies Tamar Green1, Paige E
    Green et al. Journal of Neurodevelopmental Disorders (2017) 9:25 DOI 10.1186/s11689-017-9205-x REVIEW Open Access Attention deficit hyperactivity disorder (ADHD) in phenotypically similar neurogenetic conditions: Turner syndrome and the RASopathies Tamar Green1, Paige E. Naylor2 and William Davies3,4,5* Abstract Background: ADHD (attention deficit hyperactivity disorder) is a common neurodevelopmental disorder. There has been extensive clinical and basic research in the field of ADHD over the past 20 years, but the mechanisms underlying ADHD risk are multifactorial, complex and heterogeneous and, as yet, are poorly defined. In this review, we argue that one approach to address this challenge is to study well-defined disorders to provide insights into potential biological pathways that may be involved in idiopathic ADHD. Main body: To address this premise, we selected two neurogenetic conditions that are associated with significantly increased ADHD risk: Turner syndrome and the RASopathies (of which Noonan syndrome and neurofibromatosis type 1 are the best-defined with regard to ADHD-related phenotypes). These syndromes were chosen for two main reasons: first, because intellectual functioning is relatively preserved, and second, because they are strikingly phenotypically similar but are etiologically distinct. We review the cognitive, behavioural, neural and cellular phenotypes associated with these conditions and examine their relevance as a model for idiopathic ADHD. Conclusion: We conclude by discussing current and future opportunities
    [Show full text]
  • Supplementary Table 1
    SUPPLEMENTARY TABLE I: Genes dysregulated with overexpression of HIF-2α in LP-1 cells. GeneID Gene Symbol Gene Name Fold Change Regulation in LP-1-HIF2A NM_001430 EPAS1 endothelial PAS domain protein 1/hypoxia-inducible factor 2α 40.71 up NM_001295 CCR1 chemokine (C-C motif) receptor 1 6.48 up NM_001010923 THEMIS thymocyte selection associated 5.14 up NM_000609 CXCL12 chemokine (C-X-C motif) ligand 12 4.65 up NM_017738 CNTLN centlein, centrosomal protein 4.03 up NM_001012301 ARSI arylsulfatase family, member I 3.99 up 10628 TXNIP thioredoxin interacting protein 3.81 up NM_003633 ENC1 ectodermal-neural cortex 1 (with BTB domain) 3.38 up NM_000351 STS steroid sulfatase (microsomal), isozyme S 3.23 up NM_007315 STAT1 signal transducer and activator of transcription 1 3.19 up NM_001175 ARHGDIB Rho GDP dissociation inhibitor (GDI) beta 3.14 up NM_021982 SEC24A SEC24 family member A 3.04 up NM_001876 CPT1A carnitine palmitoyltransferase 1A 3.01 up 57226 LYRM2 LYR motif containing 2 2.99 up NM_019058 DDIT4 DNA-damage-inducible transcript 4 2.96 up NM_004419 DUSP5 dual specificity phosphatase 5 2.88 up NM_021623 PLEKHA2 pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 2 2.74 up NM_022350 ERAP2 endoplasmic reticulum aminopeptidase 2 2.73 up NM_005779 LHFPL2 lipoma HMGIC fusion partner-like 2 2.68 up NM_197947 CLEC7A C-type lectin domain family 7, member A 2.67 up ENST00000334286 EDNRB endothelin receptor type B 2.62 up AK289800 SLC35D1 solute carrier family 35 (UDP-GlcA/UDP-GalNAc transporter), member D1
    [Show full text]